Contract Option Exercises — March 26, 2026

Westat ($505M PATH Study), PPD ($126M COVID assays), and Advanced Technology ($161M biotech) secure $792M obligations, with Westat and PPD bullish due to outlays of $213M and $23M.

AATD LLC's $138M obligated delivery order (122M outlayed) under SDVOSB set-aside offers upside to $423M base+options through 2026.

Acacia's $832M DOI contract (779M outlayed) for refugee legal services provides funding flow but no public equity exposure as tax-exempt.

Low outlays in early-stage contracts signal execution delays (e.g., Advanced Technology $240k vs $161M; PPD $23M vs $126M)

COVID-focused R&D vulnerable to shifting priorities (PPD immunogenicity assays); long tenors to 2029 expose to funding cuts

T&M and cost-plus structures cap billing rates and depend on hours justification (Acacia, Westat, PPD)

$707M unexercised options across contracts (e.g., Westat $455M upside, AATD $285M)

BARDA biotech/COVID R&D awards signal follow-on potential ($287M obligated)

SDVOSB/8(a) set-asides favor AATD for recurring VA IT contracts ($423M ceiling)

45% of value ($792M) in long-term (to 2029) R&D contracts for tobacco, biotech, COVID vaccines, with bullish for-profits showing outlay momentum.

47% value ($832M) in Acacia's refugee legal services with 94% outlayed, but neutral due to tax-exempt status.

SDVOSB set-aside enables AATD's $138M scaling to $423M in endpoint services.

{"entity"=>"Westat, Inc.", "reason"=>"$505M PATH Study with $455M options through 2028 offers largest for-profit upside", "trigger"=>"option exercise >$100M or outlays exceeding $300M"}

{"entity"=>"AATD LLC", "reason"=>"Strong 88% outlay rate on $138M VA IT; SDVOSB status positions for repeats", "trigger"=>"new VA delivery orders or full $423M obligation"}

{"entity"=>"PPD DEVELOPMENT LP", "reason"=>"$126M BARDA COVID R&D to 2029 at risk from priority shifts but fully committed", "trigger"=>"outlays doubling to $50M+ or BARDA extensions"}

{"entity"=>"HHS BARDA pipeline", "reason"=>"Cluster of 2023 awards ($287M) indicates biotech momentum", "trigger"=>"new task orders >$100M"}